LQDA — Liquidia Corporation
$42.65+7.46%
Last close: · regular session
After-hours $42.36 -0.68% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for LQDA in the TickerWise workspace.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Company profile
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 170
- Website: https://www.liquidia.com
Latest SEC filings for LQDA
Latest LQDA news
- Liquidia soars 27% after settlement resolves litigation Read article
- LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label Read article
- Liquidia adds over 30% on United Thera. settlement; BTIG upgrades Read article
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation Read article
- United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42% Read article
- Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday Read article
- Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battle Read article
- Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.